PMCB · PharmaCyte Biotech, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Any such required financing may not be available in amounts or on terms acceptable to us, and the failure to procure such required financing could have a material and adverse effect on our business, financial condition and results of operations, or threaten our ability to continue as a going concern.”View the 10-K filed Jul 29, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-03-31 | WALKER WAYNE REMELL |
Director |
Other↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported grant was made in error and has been cancelled. |
Stock Option (Right to Buy)
|
0 |
| 2026-03-31 | SCHECHTER JONATHAN |
Director |
Other↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported grant was made in error and has been cancelled. |
Stock Option (Right to Buy)
|
0 |
| 2026-03-31 | Abecassis Michael M |
Director |
Other↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported grant was made in error and has been cancelled. |
Stock Option (Right to Buy)
|
0 |
| 2026-03-31 | WEINSTEIN ROBERT |
Director |
Other↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported grant was made in error and has been cancelled. |
Stock Option (Right to Buy)
|
0 |
| 2026-01-07 | SCHECHTER JONATHAN |
Director |
Buy↑
|
Common Stock
|
20,000 |
| 2026-01-07 | Silverman Joshua |
Director |
Buy↑
|
Common Stock
|
40,000 |
| 2026-01-06 | SCHECHTER JONATHAN |
Director |
Buy↑
|
Common Stock
|
20,000 |
| 2026-01-06 | Silverman Joshua |
Director |
Buy↑
|
Common Stock
|
30,000 |
| 2026-01-05 | Silverman Joshua |
Director |
Buy↑
|
Common Stock
|
30,000 |
| 2026-01-05 | SCHECHTER JONATHAN |
Director |
Buy↑
|
Common Stock
|
20,000 |
| 2025-12-12 | Silverman Joshua |
Director |
Award↑
|
Common Stock
|
575,000 |
| 2025-12-12 | Silverman Joshua |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. |
Common Stock
|
258,750 |
| 2025-12-12 | WEINSTEIN ROBERT |
Director |
Award↑
|
Common Stock
|
75,000 |
| 2025-12-12 | WEINSTEIN ROBERT |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. |
Common Stock
|
33,750 |
| 2025-12-12 | WALKER WAYNE REMELL |
Director |
Award↑
|
Common Stock
|
37,500 |
| 2025-12-12 | SCHECHTER JONATHAN |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. |
Common Stock
|
67,500 |
| 2025-12-12 | WALKER WAYNE REMELL |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. |
Common Stock
|
16,875 |
| 2025-12-12 | Abecassis Michael M |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. |
Common Stock
|
16,875 |
| 2025-12-12 | Abecassis Michael M |
Director |
Award↑
|
Common Stock
|
37,500 |
| 2025-12-12 | SCHECHTER JONATHAN |
Director |
Award↑
|
Common Stock
|
150,000 |
| 2025-04-25 | WALKER WAYNE REMELL |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker. This transaction is late due to an inadvertent administrative error and not any error of Mr. Walker. |
Stock Option (Right to Buy)
|
63,233 |
| 2025-04-25 | WEINSTEIN ROBERT |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Weinstein. This transaction is late due to an inadvertent administrative error and not any error of Mr. Weinstein. |
Stock Option (Right to Buy)
|
63,233 |
| 2025-04-25 | SCHECHTER JONATHAN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter. This transaction is late due to an inadvertent administrative error and not any error of Mr. Schechter. |
Stock Option (Right to Buy)
|
63,233 |
| 2025-04-25 | Abecassis Michael M |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis. This transaction is late due to an inadvertent administrative error and not any error of Mr. Abecassis. |
Stock Option (Right to Buy)
|
63,233 |
| 2024-04-30 | SCHECHTER JONATHAN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter. This transaction is late due to an inadvertent administrative error and not any error of Mr. Schechter. |
Stock Option (Right to Buy)
|
38,009 |
| 2024-04-30 | WEINSTEIN ROBERT |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Weinstein. This transaction is late due to an inadvertent administrative error and not any error of Mr. Weinstein. |
Stock Option (Right to Buy)
|
38,009 |
| 2024-04-30 | Abecassis Michael M |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis. This transaction is late due to an inadvertent administrative error and not any error of Mr. Abecassis. |
Stock Option (Right to Buy)
|
38,009 |
| 2024-04-30 | WALKER WAYNE REMELL |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker. This transaction is late due to an inadvertent administrative error and not any error of Mr. Walker. |
Stock Option (Right to Buy)
|
38,009 |
| 2023-11-20 | Abecassis Michael M |
Director |
Award↑
|
Stock Option (Right to Buy)
|
61,248 |
| 2023-11-20 | SCHECHTER JONATHAN |
Director |
Award↑
|
Stock Option (Right to Buy)
|
61,248 |
| 2023-11-20 | Trujillo Carlos |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest 50% on November 20, 2023 and 50% on November 20, 2024. |
Stock Option (Right to Buy)
|
85,000 |
| 2023-11-20 | WEINSTEIN ROBERT |
Director |
Award↑
|
Stock Option (Right to Buy)
|
61,248 |
| 2023-11-20 | WALKER WAYNE REMELL |
Director |
Award↑
|
Stock Option (Right to Buy)
|
61,248 |
| 2023-11-20 | Silverman Joshua |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest 50% on November 20, 2023 and 50% on November 20, 2024. |
Stock Option (Right to Buy)
|
170,000 |
| 2022-12-28 | Allen Daniel |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option grant was approved by the Issuer's board of directors on November 14, 2022, subject to stockholder approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), under which the option was granted. The Issuer's stockholders approved the 2022 Plan on December 28, 2022. |
Stock Option (Right to Buy)
|
125,000 |
| 2022-12-28 | Farb Daniel Stuart |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option grant was approved by the Issuer's board of directors on November 14, 2022, subject to stockholder approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), under which the option was granted. The Issuer's stockholders approved the 2022 Plan on December 28, 2022. |
Stock Option (Right to Buy)
|
125,000 |
| 2022-12-28 | WALKER WAYNE REMELL |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2022-11-14 | WEINSTEIN ROBERT |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2022-08-15 | STOVER JACK E |
Insider |
Other↑
|
No Securities Owned
|
0 |